glp-1 agonists and pancreatitis american diabetes association history receptor agonist 🚨 GLP-1s & Pancreatitis: What the GLP-1–Based Therapies: The Dilemma of

Although this difference approached but did not reach the threshold for clinical significance established in other studies,134 the findings suggest the potential neuroprotective effects of lixisenatide, possibly mediated by increased synaptic dopamine levels, as supported by preclinical and clinical research in addictive disorders.135,136 Further investigations are warranted to elucidate the mechanisms underlying GLP-1RAs action in PD

Candow DG, Little JP, Chilibeck PD, Abeysekara S, Zello GA, Kazachkov M, et al

Preliminary studies show promising reductions in body weight, apneahypopnea index (AHI), and systemic inflammation, although long-term trials remain warranted

[4] Ward, Z

Zhou W, Chen G, Chen D, Ye H, Zeng X